Cargando…
O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Pacini Editore SpA
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235874/ |
| _version_ | 1782218652672589824 |
|---|---|
| author | Angelini, C. Semplicini, C. Pegoraro, E. Filosto, M. Marrosu, G. Piras, R. Mongini, T. Vercelli, L. Tonin, P. Servidei, S. Di Giacopo, R. Crescimanno, G. Ravaglia, S. Toscano, A. Musumeci, O. Siciliano, G. Ricci, G. Di Iorio, Cipullo, F. Moggio, M. Comi, G. Lucchini, V. Morandi, L. |
| author_facet | Angelini, C. Semplicini, C. Pegoraro, E. Filosto, M. Marrosu, G. Piras, R. Mongini, T. Vercelli, L. Tonin, P. Servidei, S. Di Giacopo, R. Crescimanno, G. Ravaglia, S. Toscano, A. Musumeci, O. Siciliano, G. Ricci, G. Di Iorio, Cipullo, F. Moggio, M. Comi, G. Lucchini, V. Morandi, L. |
| author_sort | Angelini, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3235874 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Pacini Editore SpA |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-32358742012-01-20 O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients Angelini, C. Semplicini, C. Pegoraro, E. Filosto, M. Marrosu, G. Piras, R. Mongini, T. Vercelli, L. Tonin, P. Servidei, S. Di Giacopo, R. Crescimanno, G. Ravaglia, S. Toscano, A. Musumeci, O. Siciliano, G. Ricci, G. Di Iorio, Cipullo, F. Moggio, M. Comi, G. Lucchini, V. Morandi, L. Acta Myol Oral Presentations Pacini Editore SpA 2011-10 /pmc/articles/PMC3235874/ Text en The journal and the individual contributions contained in it are protected by the copyright of Gaetano Conte Academy, Naples, Italy http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Oral Presentations Angelini, C. Semplicini, C. Pegoraro, E. Filosto, M. Marrosu, G. Piras, R. Mongini, T. Vercelli, L. Tonin, P. Servidei, S. Di Giacopo, R. Crescimanno, G. Ravaglia, S. Toscano, A. Musumeci, O. Siciliano, G. Ricci, G. Di Iorio, Cipullo, F. Moggio, M. Comi, G. Lucchini, V. Morandi, L. O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients |
| title | O-3
Clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset GSD II patients |
| title_full | O-3
Clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset GSD II patients |
| title_fullStr | O-3
Clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset GSD II patients |
| title_full_unstemmed | O-3
Clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset GSD II patients |
| title_short | O-3
Clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset GSD II patients |
| title_sort | o-3
clinical features and outcome measures during
1 year enzyme replacement therapy in late
onset gsd ii patients |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235874/ |
| work_keys_str_mv | AT angelinic o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT semplicinic o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT pegoraroe o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT filostom o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT marrosug o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT pirasr o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT monginit o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT vercellil o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT toninp o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT servideis o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT digiacopor o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT crescimannog o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT ravaglias o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT toscanoa o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT musumecio o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT sicilianog o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT riccig o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT diiorio o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT cipullof o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT moggiom o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT comig o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT lucchiniv o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients AT morandil o3clinicalfeaturesandoutcomemeasuresduring1yearenzymereplacementtherapyinlateonsetgsdiipatients |